Immutep Limited logo
Immutep Limited IMMP
$ 0.3 -3.64%

Annual report 2025
added 04-11-2026

report update icon

Immutep Limited EPS Ratio 2011-2026 | IMMP

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Immutep Limited

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - -5.03 -3.36 -0.57 -0.49 -0.41 -2.78 - - - - -

All numbers in AUD currency

Indicator range from annual reports

Maximum Minimum Average
-0.41 -5.03 -2.11

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-15.4 - 2.43 % $ 254 M germanyGermany
Aligos Therapeutics Aligos Therapeutics
ALGS
-2.45 $ 8.48 6.0 % $ 83.8 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-0.53 $ 3.66 -1.48 % $ 8.81 B australiaAustralia
I-Mab I-Mab
IMAB
-7.66 - - $ 866 M chinaChina
AlloVir AlloVir
ALVR
-2.85 - 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-3.25 - - $ 10.1 M usaUSA
Genfit SA Genfit SA
GNFT
1.51 - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-0.26 - -13.47 % $ 169 M franceFrance
Esperion Therapeutics Esperion Therapeutics
ESPR
-0.11 $ 2.19 0.92 % $ 455 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
-0.83 $ 0.78 -4.39 % $ 27.9 M israelIsrael
Applied Therapeutics Applied Therapeutics
APLT
-1.42 - - $ 8.42 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-31 - -18.52 % $ 27.3 M britainBritain
Genmab A/S Genmab A/S
GMAB
34.4 $ 28.2 -0.18 % $ 18 B danmarkDanmark
Grifols, S.A. Grifols, S.A.
GRFS
0.28 $ 8.38 2.01 % $ 6.83 B spainSpain
GT Biopharma GT Biopharma
GTBP
-6.68 $ 0.38 2.47 % $ 2.1 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
2.1 $ 21.28 4.44 % $ 995 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
2.64 $ 66.92 -1.33 % $ 8.02 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
-204 - -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-6.62 - - $ 86.2 M usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
2.76 $ 29.05 0.55 % $ 1.67 B usaUSA
Advaxis Advaxis
ADXS
-7.99 - -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-0.07 - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
-1.91 - -10.17 % $ 12.2 K usaUSA
Immatics N.V. Immatics N.V.
IMTX
-4.77 $ 10.87 4.17 % $ 684 M germanyGermany
Incyte Corporation Incyte Corporation
INCY
6.59 $ 95.33 -0.77 % $ 18.6 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-24.9 - - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
-0.02 $ 1.46 4.29 % $ 375 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-0.36 - - $ 26.5 M usaUSA
Allakos Allakos
ALLK
-2.14 - - $ 28.6 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-5.97 $ 2.99 2.4 % $ 4.92 M israelIsrael
Aptinyx Aptinyx
APTX
-0.96 - -39.0 % $ 4.57 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
-0.78 $ 4.2 2.82 % $ 449 M usaUSA
Aravive Aravive
ARAV
-2.1 - -13.39 % $ 1.45 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
-0.13 $ 24.24 0.1 % $ 3.08 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
-0.66 $ 1.47 4.26 % $ 235 M franceFrance
AIkido Pharma AIkido Pharma
AIKI
-1.57 - 1.93 % $ 17.4 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
-3.9 $ 32.59 1.09 % $ 2.16 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-1.08 $ 1.48 -0.67 % $ 394 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
-10.4 - -45.71 % $ 1.2 M canadaCanada
Cidara Therapeutics Cidara Therapeutics
CDTX
-26.8 - - $ 1.41 B usaUSA
AVROBIO AVROBIO
AVRO
0.27 - 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-2.46 - - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
0.08 - - $ 96.9 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
-3.75 - - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-2.21 - - $ 867 M germanyGermany
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-1.11 - -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
0.2 - 0.49 % $ 251 B cayman-islandsCayman-islands